Plus Therapeutics Q3 net loss $3.2M ($1.00/share); cash $11M, runway into 2025

PLUS THERAPEUTICS, INC.

2023-Q3 EPS reported -$3.54

Net loss $3.2M ($1.00 per share) vs $5.2M ($2.85) in Q3 2022; operating expenses $4.5M.
Cash $11M at Sep 30, 2023; plus $10.2M expected from CPRIT grant through 2024, providing runway into 2025.
Completed dosing in Cohort 4 of Phase 1 ReSPECT-LM trial; new survival data from Phase 2 ReSPECT-GBM to be presented at SNO Nov 2023.
Appointed Pius Maliakal, Ph.D. as VP of Clinical Operations; transferred CNSide biomarker assay from Biocept.
Grant revenue $1.2M in Q3 from CPRIT; total grant awards $3M from NIH and $17.6M from CPRIT.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PLUS THERAPEUTICS, INC. reported third quarter ended September 30, 2023 results: net income $(3.2) million, or $(1.00) per share, EPS $(1.00) per share.

Period: third quarter ended September 30, 2023
Net income: $(3.2) million, or $(1.00) per share
EPS: $(1.00) per share
Result: reported results

Exact text from the filing

Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-267200

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.